Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Rexahn Pharmaceuticals forms Parkinson’s Disease SAB to develop strategy for Serdaxin

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced the formation of its Parkinson’s Disease Scientific Advisory Board (SAB), featuring some of the leading medical researchers in neurology.

22 Mar 2010

CRT, Cephalon to collaborate on development of small molecule inhibitors against cancer

Cancer Research Technology has announced an exclusive agreement with Cephalon, Inc., an international biotechnology company, to collaborate on the development of small molecule inhibitors. These molecules will target specific members of the 'protein kinase C' superfamily of cell signalling proteins - which have been shown to be associated with the development of cancer.

22 Mar 2010

BEMA Granisetron development program: BDSI announces positive meeting with FDA

BioDelivery Sciences International, Inc. announced the positive outcome of a meeting with the FDA on the development program for BEMA Granisetron, the company’s potential treatment for the prevention of nausea and vomiting associated with cancer therapy. FDA concurred with BDSI’s plans to pursue a development program based on clinical pharmacokinetic data for a 505(b)(2) New Drug Application.

22 Mar 2010

BSD Medical files 510(k) submission for premarket clearance of Phase II MTX-180

BSD Medical Corporation today announced that the Company has filed a 510(k) submission with the U.S. Food and Drug Administration for premarket clearance of the Company's Phase II MicroThermX® Microwave Ablation System for ablation of soft tissue.

22 Mar 2010

First patient dosed in NCI-sponsored Phase 1/2 trial of belinostat

Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a primary focus in oncology and hematology, and TopoTarget A/S, today announced that the first patient has been dosed in a National Cancer Institute -sponsored Phase 1/2 trial of belinostat in combination with cisplatin, doxorubicin and cyclophosphamide in the first line treatment of advanced or recurrent thymic malignancies.

22 Mar 2010

Calando Pharmaceuticals demonstrates first targeted siRNA-containing nanoparticle delivery to tumors

Arrowhead Research Corporation today announced that the clinical trial being conducted by majority-owned subsidiary, Calando Pharmaceuticals, Inc., has demonstrated systemic delivery of siRNA and the successful “silencing” of a widely recognized cancer gene via RNA interference (RNAi) in humans.

22 Mar 2010

Simcere Pharmaceutical completes Phase IV clinical study of Endostar

Simcere Pharmaceutical Group, a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endostar (also known as Endu) in China, announced today the successful completion of Endostar Phase IV clinical study at a conference in Beijing dedicated to this study.

22 Mar 2010

Chao BRAIN Center receives $5M gift for study of progressive neurodegenerative diseases

Dr. Stephen Wong has received a $5 million gift from the Ting Tsung and Wei Fong Chao Foundation to study progressive neurodegenerative diseases including Alzheimer's Disease. The gift will support The Ting Tsung and Wei Fong Chao Center for Bioinformatics Research and Imaging for Neurosciences (BRAIN) at The Methodist Hospital Research Institute.

22 Mar 2010

ILSI Biomed Israel 2010 international conference to be held in Tel Aviv

Set against the backdrop of the global market recovery and the recent proliferation of the life sciences field, this June’s ILSI Biomed Israel 2010 international conference will be attended by the most prominent figures in the biotechnology, pharma and medical device sectors.

22 Mar 2010

Asuragen appoints BMD as exclusive distributor of Signature Oncology Products in France

Asuragen, Inc., a leader in the development of molecular diagnostics, announced today the appointment of Biomedical Diagnostics SA, a leading medical diagnostic company in Europe, as its exclusive distributor of Signature® Oncology Products in France. Asuragen’s Signature Oncology Portfolio comprises multiplex assays for the detection of mutations in solid and hematologic malignancies.

22 Mar 2010

Nanotechnology weapons for cancer

US Researchers have come up with new nanoparticle robots that are essentially a tiny army that can travel in the blood till they reach the cancers and then tweak some important cancer causing genes that can cure the cancer.

22 Mar 2010

Mayo Clinic co-led research finds first gene linked to lung cancer in "never smokers"

A five-center collaborative study that scanned the genomes of thousands of "never smokers" diagnosed with lung cancer as well as healthy never smokers has found a gene they say could be responsible for a significant number of those cancers.

22 Mar 2010

EUREKA project develops unique range of antibodies

EUREKA project E! 3424 RECAN has developed a range of unique and highly specific monoclonal and polyclonal antibodies - the proteins produced in the blood which counteract bacteria, viruses or cancerous cells.

20 Mar 2010

BioDelivery Sciences International announces filing of Annual Report with U.S. SEC

BioDelivery Sciences International, Inc. has filed its Annual Report with the U.S. Securities and Exchange Commission on Form 10-K for the fiscal year ended December 31, 2009. Such Form 10-K is available on the SEC’s website at www.sec.gov.

20 Mar 2010

Safe to smoke?

Some Australian scientists have found that there is a new agent that can protect the lungs of mice from the harmful effects of cigarette smoke.

19 Mar 2010

Community-driven approaches needed for reducing cancer-death disparities

Cancer death rates for African-Americans far exceed non-Hispanic Caucasians in the United States, and only community-driven approaches to reducing health disparities will lessen the gap, says Edward Partridge, M.D., president-elect of the American Cancer Society (ACS) National Board of Directors and director of the University of Alabama at Birmingham (UAB) Comprehensive Cancer Center.

19 Mar 2010

European CHMP issues positive opinion for Roche's Tarceva as maintenance therapy for NSCLC

Roche today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for use of Tarceva(R) (erlotinib) as a maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) and stable disease (cancer remains largely unchanged) after initial chemotherapy. The CHMP positive opinion clears the way for European Union approval and means that this group of patients may soon be able to benefit from earlier treatment with Tarceva.

19 Mar 2010

CHMP issues positive opinion recommending approval of Tarceva as monotherapy for NSCLC

OSI Pharmaceuticals, Inc. announced today that its international partner for Tarceva® (erlotinib), Roche, informed OSI that the European Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of Tarceva as monotherapy for maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with stable disease following four cycles of standard platinum-based first-line chemotherapy.

19 Mar 2010

Hercules Technology Growth Capital commits over $52.0M in structured debt financing

Hercules Technology Growth Capital, Inc., the leading specialty finance company providing venture debt and equity to venture capital and private equity-backed technology and life science companies at all stages of development, today announced that it has committed over $52.0 million in structured debt financing to new and existing portfolio companies.

19 Mar 2010

Abstract about Phase I/II trial of ThermoDox in RCW accepted for presentation at ASCO 2010

Celsion Corporation today announced that an abstract about the Phase I/II trial of ThermoDox® in Recurrent Chest Wall Cancer (RCW) has been accepted for presentation at the American Society of Clinical Oncology 2010 Annual Meeting.

19 Mar 2010

Oncology News and Research

Further Reading

Rexahn Pharmaceuticals forms Parkinson’s Disease SAB to develop strategy for Serdaxin

CRT, Cephalon to collaborate on development of small molecule inhibitors against cancer

BEMA Granisetron development program: BDSI announces positive meeting with FDA

BSD Medical files 510(k) submission for premarket clearance of Phase II MTX-180

First patient dosed in NCI-sponsored Phase 1/2 trial of belinostat

Calando Pharmaceuticals demonstrates first targeted siRNA-containing nanoparticle delivery to tumors

Simcere Pharmaceutical completes Phase IV clinical study of Endostar

Chao BRAIN Center receives $5M gift for study of progressive neurodegenerative diseases

ILSI Biomed Israel 2010 international conference to be held in Tel Aviv

Asuragen appoints BMD as exclusive distributor of Signature Oncology Products in France

Nanotechnology weapons for cancer

Mayo Clinic co-led research finds first gene linked to lung cancer in "never smokers"

EUREKA project develops unique range of antibodies

BioDelivery Sciences International announces filing of Annual Report with U.S. SEC

Safe to smoke?

Community-driven approaches needed for reducing cancer-death disparities

European CHMP issues positive opinion for Roche's Tarceva as maintenance therapy for NSCLC

CHMP issues positive opinion recommending approval of Tarceva as monotherapy for NSCLC

Hercules Technology Growth Capital commits over $52.0M in structured debt financing

Abstract about Phase I/II trial of ThermoDox in RCW accepted for presentation at ASCO 2010

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News